« Back to Record
Citation APA

Sotiriou, C., Venet, D., Fumagalli, D., Maetens, M. M., Rothé, F., Ignatiadis, M., Bradbury, I., Harbeck, N., Gomez, H., Chang, T., Coccia-Portugal, M., Di Cosimo, S., de Azambuja, E., de la Peña, L., Armour, A., Eidtmann, H., Baselga, J., Piccart-Gebhart, M., & Loi, S. (2015). Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial. Online Abstract session presented at 18th ECCO - 40th ESMO European Cancer Congress(Vienna, Austria)


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/222298

Sotiriou, C., Venet, D., Fumagalli, D., Maetens, M. M., Rothé, F., Ignatiadis, M., Bradbury, I., Harbeck, N., Gomez, H., Chang, T., Coccia-Portugal, M., Di Cosimo, S., de Azambuja, E., de la Peña, L., Armour, A., Eidtmann, H., Baselga, J., Piccart-Gebhart, M., & Loi, S. (2015). Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial. Online Abstract session presented at 18th ECCO - 40th ESMO European Cancer Congress(Vienna, Austria)